CD9 Antibody HI9a validation using 3 peak antibody binding beads demonstrates clear resolution of 3 bead populations. Peaks correspond to signal measured from 0, 200, and 1000 antibodies. Measurement was performed on a Beckman Coulter CytoFlex equipped with a 561nm laser.
CD9 Antibody HI9a validation using 3 peak antibody binding beads demonstrates clear resolution of 3 bead populations. Peaks correspond to signal measured from 0, 200, and 1000 antibodies. Measurement was performed on a Beckman Coulter CytoFlex equipped with a 561nm laser.
Validation of Anti-CD9 vTag™ Antibody HI9a [PE] in vFC™ staining. (A) vFC™ count and size of platelet derived extracellular vesicles (EVs), a positive control sample for CD9 staining; (B) Anti-CD9 vTag™ staining of platelet derived EVs (120 second acquisition time, for more details see our vFC™ assay and protocol); (C) Anti-CD9 vTag™ staining of negative control samples (Lipo100™); (D) Positive (B) and negative (C) control data summarized and merged for comparison.

vTAG™ ANTI-HUMAN CD9 ANTIBODY
NO WASH, QUANTITATIVE CD9 MEASUREMENT BY vFC™

$105.00 – $295.00

Conjugate(s): PE
Est. Limit of Detection: 30 Molecules per EV

 

Cargo analysis using vTag™ antibodies should be accompanied by a vesicle specific analysis method such as vFC™. vTag™ antibodies bundled with the vFC™ assay will be discounted 25%.
Certificate of Analysis
TDS MSDS
SKU: CBS10 Category:

Description

Product Attributes

Tested Reactivity: Anti-Human.
Other Published Reactivity: Baboon, Bovine, Canine, Cynomolgus, Equine, Ovine, Rabbit, and Rhesus.
Conjugate: PE (see dropdown at the top for available options).
Sensitivity: Limit of detection is estimated at 30 molecules per vesicle in vFC™ for the PE conjugate. Change selection above for LOD of the antibody conjugated to a different fluorophore. LOD is estimated using antibody binding beads and will vary depending upon sample, instrument, and other experimental conditions.
Application: Optimized for vFC™ with no wash steps required.
Clonality: Monoclonal.
Clone: HI9a.
Host and Isotype: Mouse IgG1, kappa.
Positive Control Sample: Platelet derived EVs.
Localization of Staining: Vesicle Surface.
Buffer and Stabilizer: 10mM PBS with 0.05% BSA & 0.05% azide.
Concentration: 5 ul/test.
Purification Method: Affinity purified.
Immunogen: Human PBMCs.
Storage Conditions: Store undiluted between 2°C and 8°C. Protected from prolonged exposure to light. Do not freeze. Stable for 1 year when properly stored.

Protocols

CD9 Immunostaining in vFC™?

vFC™ (#CBS4) is an assay that enables specific detection and characterization of individual extracellular vesicles such as exosomes and microvesicles on commercially available flow cytometers. This protocol makes use of vFC™ to provide a standardized means of analyzing individual vesicles to measure size, concentration, and CD9 expression simultaneously. Because vFC™ triggers on vesicles, pairing antibody staining with vFC™ enables a highly-reproducible, no-wash assay. In this protocol, vesicles will be stained using our vTag™ Anti-Human CD9 Antibody. See protocol 2 in the vFC™ kit handbook for additional considerations and full protocol details.

Procedure

  1. Dilute sample containing EVs to approximately 5×106 extracellular vesicles per µl. To empirically determine vesicle concentration, see supporting protocols included in the vFC™ kit.
  2. Prepare a working concentration of vFluor™ Red (5 µl per well) according to kit instructions
  3. In duplicate, in the included 96 well plate, add 35 µl of dilution buffer, 5µl of vFluor™ Red, 5 µl of vTag™ anti-human CD9 antibody, and 5 µl of EV sample.
  4. Incubate in the dark for 1hr.
  5. Perform serial dilution of the samples as described in the assay handbook. Briefly, samples are to be diluted from between 1:100 to 1:1000 from staining concentration depending upon the flow cytometer being used.
  6. Analyze the diluted sample of labeled EVs on a qualified flow cytometer.

CD9 Background Information

CD9 is a member of the tetraspanin family. In cells, tetraspanins are importnat to many biological functions including cell adhesion and motility as well as signaling and protein trafficking.

CD9 was first reported in EVs from dendritic cells (which were described as exosomes). It is abundant in the membrane of many cells and is present in larger membrane EVs. CD9 has broad tissue distribution and is one of several molecules previously thought to be useful as a pan exosome or extracellular vesicle marker. Of course, we now know that EVs from different sources exhibit different tetraspanin expression profiles which suggests that different tetraspanins will serve as markers for different vesicle subpopulations. For instance, in our own work profiling EV cargo in vesicles originating from distinct subsets of cells, we have found that CD9 is highly expressed in vesicles derived from various immune cell populations, certain carcinoma cell lines, and platelet derived EVs. However, CD9 expression is very low or absent in vesicles derived from red blood cells and the glioblastoma cell line U87MG (see the data by vesicle origin resource for more info).

Additional information

Size

20 Tests, 100 Tests
Conjugate

PE, PE-Cy7

Reviews

There are no reviews yet.

Be the first to review “vTAG™ ANTI-HUMAN CD9 ANTIBODY
NO WASH, QUANTITATIVE CD9 MEASUREMENT BY vFC™
”

CD9 Antibody HI9a validation using 3 peak antibody binding beads demonstrates clear resolution of 3 bead populations. Peaks correspond to signal measured from 0, 200, and 1000 antibodies. Measurement was performed on a Beckman Coulter CytoFlex equipped with a 561nm laser.
vTAG™ ANTI-HUMAN CD9 ANTIBODY
NO WASH, QUANTITATIVE CD9 MEASUREMENT BY vFC™
$105.00 – $295.00
https://www.cellarcus.com/wp-content/uploads/2019/04/CD9-vTag-EV-staining-data-300x300.jpg
0